NKore BioTherapeutics develops an allogeneic cellular immunotherapy platform focused on treating cancer and immune-related diseases. The company utilizes a proprietary method to activate natural killer (NK) cells, creating significantly more potent Supercharged Natural Killer (sNK) cells. This approach aims to provide a non-toxic treatment option with enhanced cytotoxicity against cancer cells, reducing the risk of tumor regeneration and metastasis.
Funding
$4.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often fail to eliminate cancer stem cells, leading to tumor regeneration, metastasis, and reduced patient resilience, particularly in pediatric cancer cases where treatment options are limited. Existing immunotherapies may also have limited effectiveness due to defects in natural killer (NK) cell function within the tumor microenvironment.
Solution
NKore BioTherapeutics is developing a cellular-based immunotherapy platform that utilizes allogeneic, "supercharged" natural killer (sNK) cells to target and eliminate cancer stem cells and poorly differentiated tumors. Their proprietary activation method enhances NK cell cytotoxicity and reduces the likelihood of tumor regeneration and metastasis. NKore's approach aims to improve patient outcomes by restoring and enhancing the innate immune system's ability to combat cancer, either as a standalone therapy or in combination with existing treatments. Preclinical studies in humanized mice have demonstrated that sNK cells can induce tumor inhibition and differentiation. The company is also exploring the use of synthetic cannabinoids to further enhance NK cell function and target cancer stem cells.
Target Audience
The primary target audience includes oncologists, hospitals, and cancer research institutions focused on developing novel immunotherapies, particularly for patients with cancers that are difficult to treat with conventional methods or who have limited treatment options, including pediatric cancer patients.
Features
- Proprietary method for activating and "supercharging" allogeneic natural killer (NK) cells
- Enhanced cytotoxicity against cancer stem cells and poorly differentiated tumors
- Potential to reduce tumor regeneration and metastasis
- Ability to trigger differentiation of aggressive undifferentiated tumors
- Compatibility with other cancer treatments, including chemotherapy, radiation therapy, checkpoint inhibitors, and CAR-T therapy
- Research into synthetic cannabinoids to boost NK cell function and target cancer stem cells
- Preclinical data demonstrating tumor inhibition and differentiation in humanized mice